A carregar...
Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer
Resistance to trastuzumab is frequently observed during the treatment of patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancers. The aim of the present study was to determine if the phosphorylated proline-rich Akt substrate of 40 kDa (phospho-PRAS40(Thr246)), a novel...
Na minha lista:
| Publicado no: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4301480/ https://ncbi.nlm.nih.gov/pubmed/25621052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2014.2744 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|